References
- Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–1133. doi:10.1158/2159-8290.CD-16-059627432227
- Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–e445. doi:10.1200/JCO.2010.34.131321422405
- Yang JC, Ou SI, De Petris L, et al. Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol. 2017;12:1552–1560. doi:10.1016/j.jtho.2017.06.07028689043
- Gadgeel SM, Shaw AT, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34:4079–4085. doi:10.1200/JCO.2016.68.463927863201
- Ou SH, Gandhi L, Shaw AT, et al. Updated pooled analysis of CNS endpoints in two phase II studies of alectinib in ALK+ NSCLC. J Thorac Oncol. 2017;12(Suppl.1):MA07.01. doi:10.1016/j.jtho.2016.09.002
- Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34:661–668. doi:10.1200/JCO.2015.63.944326598747
- Camidge DR, Gadgeel S, Ou SH, et al. Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2017;12(Suppl.1):MA07.02. doi:10.1016/j.jtho.2016.11.426
- Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74:1023–1028. doi:10.1007/s00280-014-2578-625205428
- Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global Phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. [Epub ahead of print].30902613
- Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7:437–446. doi:10.1016/S2213-2600(19)30053-030981696
- Seto T, Nishio M, Hida T, et al. Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). J Clin Oncol. 2019;37(15_suppl):9092–9092S.
- Gadgeel S, Peter S, Mok T, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Ann Oncol. 2017;28(suppl_5):v605–v649. doi:10.1093/annonc/mdx440.057
- Takiguchi Y, Hida T, Nokihara H, et al. Updated efficacy and safety of the J-ALEX study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). J Clin Oncol. 2017;35(Suppl.15):Abs9064. doi:10.1200/JCO.2017.35.15_suppl.9064